Major Depressive Disorder Pipeline Insights | Clinical Trial Research Evaluation Report By DelveInsight

News provided by

Aug 24, 2022, 11:30 ET

Major depressive disorder pipeline constitutes 60+ key companies continuously working towards developing 75+ major depressive disorder treatment therapies, analyzes DelveInsight

LAS VEGAS, Aug. 24, 2022 /PRNewswire/ -- DelveInsight's 'Major Depressive Disorder Pipeline Insight 2022' report provides comprehensive global coverage of available, marketed, and pipeline major depressive disorder therapies in various stages of clinical development, major pharmaceutical companies are working to advance the pipeline space and future growth potential of the major depressive disorder pipeline domain.

Key Takeaways from the Major Depressive Disorder Pipeline Report

DelveInsight's major depressive disorder pipeline report depicts a robust space with 60+ active players working to develop 75+ pipeline therapies for major depressive disorder treatment.
Leading major depressive disorder companies such as GH Research, Praxis Precision Medicines, AbbVie, Luye Pharma Group, Gedeon Richter, Intra-Cellular Therapies, Bristol-Myers Squibb, Relmada Therapeutics, SAGE Therapeutics, Janssen Research & Development, Minerva Neurosciences, Takeda, Neurocrine Biosciences, Pherin Pharmaceuticals, XWPharma, Reviva Pharmaceuticals, Gate Neurosciences, Sirtsei Pharmaceuticals Seelos Therapeutics, Chase Therapeutics, Clexio Biosciences Ltd, VistaGen Therapeutics, Neuralstem, BioLite, Neurocrine Biosciences, MindMed, BioGen, Alector and Chase Therapeutics, Cybin others are evaluating novel major depressive disorder treatment drugs candidate to improve the treatment landscape.
Key major depressive disorder pipeline therapies in various stages of development include AXS-05, LY-03005, MIN-202, SAGE-217, REL-1017, CAPLYTA, PRAX 114, GH001, NBI-1065845, PH 10A, XW 10508 RP-5063, Zelquistinel, Apimostinel, SP-624, SLS-002, CTC-501 CLE-100, AV 101, OPC-64005, PDC 1421, NBI-1065845, MM-120, Zuranolone, AL001, SPL026, CTC-413, CYB003, GH001 and others.
In August 2022, Relmada Therapeutics announced the Food and Drug Administration (FDA) granted Fast Track designation to REL-1017 (esmethadone) as a monotherapy for the treatment of major depressive disorder (MDD). REL-1017 is a novel N-methyl-D-aspartate receptor (NMDAR) channel blocker. The investigational treatment is administered orally once daily and is designed to target hyperactive GluN1-GluN2D NMDAR channels while maintaining physiological glutamatergic neurotransmission.
In June 2022, Cybin received FDA IND Clearance for its Phase I/IIa clinical trial evaluating CYB003 for the potential treatment of Major Depressive Disorder.
In June 2022, Biogen and Sage Therapeutics announced that the Phase III SKYLARK Study of zuranolone, an investigational oral drug being evaluated in women with postpartum depression (PPD), met its primary and all key secondary endpoints. Women treated with zuranolone 50 mg (n=98) demonstrated a statistically significant and clinically meaningful improvement in depressive symptoms at Day 15, the primary endpoint, compared to placebo (n=97) as measured by a change from baseline (CFB) in the 17-item Hamilton Rating Scale for Depression (HAMD-17) total score.
In October 2021, Small Pharma granted Fast-Track Designation from the UK regulator for SPL026 DMT-Assisted therapy for Major Depressive Disorder.
In October 2021, Chase Therapeutics announced $20 million Series B financing to advance clinical trials in parkinson's disease and Major Depressive Disorder. The proceeds of the Series B will support Phase 3 pivotal trials for CTC-501 for the treatment of Major Depressive Disorder (MDD) and CTC-413 for the treatment of Parkinson's Disease (PD) as well as completion of the development and validation of a diagnostic product for Parkinson's Disease.

Request a sample and discover the recent advances in major depressive disorder treatment @Major Depressive Disorder Pipeline Report

The major depressive disorder pipeline report provides detailed profiles of pipeline assets, a comparative analysis of clinical and non-clinical stage major depressive disorder drugs, inactive and dormant assets, a comprehensive assessment of driving and restraining factors, and an assessment of opportunities and risks in the major depressive disorder pipeline landscape.

Major Depressive Disorder Overview

Major depressive disorder (MDD), commonly known as clinical depression, is a serious medical condition that can greatly impact life. It impacts mood, behavior, and physical functions such as eating and sleep. The exact major depressive disorder causes are unknown. However, several variables can raise the chances of acquiring the condition. A combination of genes and stress can change brain chemistry and impair mood stability.

Although depression can occur only once in a lifetime, most people have several episodes. The major depressive disorder symptoms occur most of the day, nearly every day. The common depressive disorder symptoms include sadness, anxiety, trouble thinking, unexplained physical problems, restlessness, and others. No blood tests, X-rays, or other laboratory tests are available for major depressive disorder diagnosis. However, the doctor may do blood tests to assist in discovering any other medical disorders that have symptoms similar to those of depression.

Find out more about MDD treatment @Major Depressive Disorder Medication

A snapshot of the Major Depressive Disorder Pipeline Drugs mentioned in the report:

Drugs	Company	Phase	MoA	RoA
SAGE-217	Sage Therapeutics	Pre-registration	GABA A receptor modulators	Oral
REL-1017	Relmada Therapeutics, Inc	Phase III	NMDA receptor antagonists	Oral
Seltorexant	Minerva Sciences	Phase III	Orexin receptor type 2 antagonists	Oral
Lumateperone	Intra-Cellular Therapies	Phase III	Dopamine D2 receptor modulators	Oral
SP-624	Sirtsei Pharmaceuticals, Inc.	Phase II	NA	Oral
SPL026	Small Pharma	Phase II	Serotonin 2A receptor agonists	Intravenous
PDC-1421	BioLite Inc	Phase II	Norepinephrine plasma membrane transport protein inhibitors	Oral
TAK 653	Takeda	Phase II	AMPA receptor modulators	Oral
PH 10	Pherin Pharmaceuticals	Phase II	Chemoreceptor cell stimulants	Intranasal
XW 10508	XWPharma	Phase I	AMPA receptor agonists	Oral

Learn more about the novel and emerging major depressive disorder pipeline therapies @Major Depressive Disorder Clinical Trials

Major Depressive Disorder Therapeutics Assessment

The major depressive disorder pipeline report proffers an integral view of the major depressive disorder emerging novel therapies segmented by stage, product type, molecule type, mechanism of action, and route of administration.

Scope of the Major Depressive Disorder Pipeline Report

Coverage: Global
Therapeutic Assessment By Product Type: Mono, Combination, Mono/Combination
Therapeutic Assessment By Clinical Stages: Discovery, Pre-clinical, Phase I, Phase II, Phase III
Therapeutics Assessment By Route of Administration: Oral, Intravenous, Subcutaneous, Intramuscular
Therapeutics Assessment By Molecule Type: Bispecific antibody, Peptide, Small molecule, Gene therapy
Therapeutics Assessment By Mechanism of Action: GABA A receptor modulators, NMDA receptor antagonists, Orexin receptor type 2 antagonists, Serotonin 2A receptor agonists, Norepinephrine plasma membrane transport protein inhibitors, Sortilin inhibitors, Serotonin 2A receptor agonists, Dopamine D2 receptor agonists; Dopamine D3 receptor agonists, Chemoreceptor cell stimulants
Key Major Depressive Disorder Companies: GH Research, Praxis Precision Medicines, AbbVie, Gedeon Richter, Intra-Cellular Therapies, Bristol-Myers Squibb, Relmada Therapeutics, SAGE Therapeutics, Janssen Research & Development, Minerva Neurosciences, Takeda, Neurocrine Biosciences, Pherin Pharmaceuticals, XWPharma, Reviva Pharmaceuticals,Gate Neurosciences, Sirtsei Pharmaceuticals Seelos Therapeutics, Chase Therapeutics,Clexio Biosciences Ltd, VistaGen Therapeutics, Neuralstem, BioLite,Neurocrine Biosciences, MindMed, BioGen, Alector and Chase Therapeutics, Cybin, and others
Key Major Depressive Disorder Pipeline Therapies: AXS-05, LY-03005, MIN-202, SAGE-217, REL-1017, CAPLYTA, PRAX 114, GH001, NBI-1065845, PH 10A, XW 10508 RP-5063, Zelquistinel, Apimostinel, SP-624, SLS-002, CTC-501 CLE-100, AV 101, OPC-64005, PDC 1421, NBI-1065845, MM-120, Zuranolone, AL001, SPL026, CTC-413, CYB003, GH001 , and others.

Dive deep into rich insights for drugs for MDD treatment, visit @New Drug for Major Depressive Disorder Treatment

Table of Contents

1.	Major Depressive Disorder Pipeline Report Introduction
2.	Major Depressive Disorder Pipeline Report Executive Summary
3.	Major Depressive Disorder Pipeline: Overview
4.	Analytical Perspective In-depth Commercial Assessment
5.	Major Depressive Disorder Clinical Trial Therapeutics
6.	Major Depressive Disorder Pipeline: Late Stage Products (Pre-registration)
7.	SAGE-217: Sage Therapeutics
8.	Major Depressive Disorder Pipeline: Late Stage Products (Phase III)
9.	REL-1017: Relmada Therapeutics
10.	Major Depressive Disorder Pipeline: Mid Stage Products (Phase II)
11.	SP-624: Sirtsei Pharmaceuticals
12.	Major Depressive Disorder Pipeline: Early Stage Products (Phase I)
13.	XW 10508: XW Pharma
14.	Major Depressive Disorder Pipeline Therapeutic Assessment
15.	Inactive Products in the Major Depressive Disorder Pipeline
13.	Company-University Collaborations (Licensing/Partnering) Analysis
14.	Key Companies
15.	Key Products in the Major Depressive Disorder Pipeline
16.	Unmet Needs
17.	Market Drivers and Barriers
18.	Future Perspectives and Conclusion
19.	Analyst Views
20.	Appendix

For further information on the major depressive disorder pipeline therapeutics, reach out @Major Depressive Disorder Drugs

Related Reports

Major Depressive Disorder Market

Major Depressive Disorder Market Insights, Epidemiology, and Market Forecast-2032 report deliver an in-depth understanding of the disease, historical and forecasted epidemiology, as well as the market trends, market drivers, market barriers, and key major depressive disorder companies including GH Research, Praxis Precision Medicines, AbbVie, among others.

Major Depressive Disorder Epidemiology Forecast

Major Depressive Disorder Epidemiology Forecast to 2032 report delivers an in-depth understanding of the disease, historical and forecasted major depressive disorder epidemiology in the 7MM, i.e., the United States, EU5 (Germany, Spain, Italy, France, and the United Kingdom), and Japan.

Treatment-resistant Depression Pipeline

Treatment-resistant Depression Pipeline Insight, 2022 report provides comprehensive insights about the pipeline landscape, pipeline drug profiles, including clinical and non-clinical stage products, and the key treatment-resistant depression companies, including Axsome Therapeutics, Sage Therapeutics, AbbVie, among others.

Treatment-resistant Depression Market

Treatment-resistant Depression Market Insights, Epidemiology, and Market Forecast-2032 report deliver an in-depth understanding of the disease, historical and forecasted epidemiology, as well as the market trends, market drivers, market barriers, and key treatment-resistant depression companies, including Axsome Therapeutics, Sage Therapeutics, AbbVie, among others.

Treatment-resistant Depression Epidemiology Forecast

Treatment-resistant Depression Epidemiology Forecast to 2032 report delivers an in-depth understanding of the disease, historical and forecasted treatment-resistant depression epidemiology in the 7MM, i.e., the United States, EU5 (Germany, Spain, Italy, France, and the United Kingdom), and Japan.

Bipolar Depression Pipeline

Bipolar Depression Pipeline Insight, 2022 report provides comprehensive insights about the pipeline landscape, pipeline drug profiles, including clinical and non-clinical stage products, and the key bipolar depression companies, including Vanda Pharmaceuticals, Sunovion, Pear Therapeutics, among others.

Other Trending Reports